Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImpedimed Ltd

Impedimed Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.004 AUD 0.00(0%)
Last update at 2026-11-12T01:41:00Z
VOLUME
250000
Market Cap
14.66M

Momentum Score

…

ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Impedimed develops and commercializes bioimpedance-based devices (L-Dex and SOZO) to detect and monitor lymphatic fluid disorders and manage body fluid in clinical and outpatient settings. Long-term growth may be supported by rising cancer survivorship, an aging population that increases lymphedema and heart-failure management needs, and recurring revenue from disposables and software; investors may find the company attractive because it occupies a focused, clinically validated niche with opportunities to expand geographies and use cases.
Principal risks include limited product diversification, dependence on clinical adoption and reimbursement, competition from alternative assessment methods, and regulatory or execution challenges when scaling internationally.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
14.61M
Revenue Per Share
0.01
Gross Profit TTM
12.77M
Debt / Equity
1.63
ROE
-162.35%
Net Debt
1.31M
ROCE
-77.60%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -26.09M -23.21M -20.73M -20.49M -19.83M
Net income -24.91M -23.24M -19.79M -20.52M -19.87M
Selling general administrative - 21.51M 22.09M 19.51M 18.15M
Selling and marketing expenses - 0.80M 0.52M 0.46M 0.67M
Gross profit -11.89M 10.97M 9.01M 9.70M 8.79M
Reconciled depreciation - 4.56M 2.25M 2.50M 2.77M
Ebit - -22.12M -24.30M -22.99M -21.54M
Ebitda -22.11M -17.55M -22.05M -20.49M -18.77M
Depreciation and amortization - 4.56M 2.25M 2.50M 2.77M
Operating income -22.11M -24.23M -19.04M -22.86M -21.47M
Other operating expenses 36.72M 36.95M 29.36M 32.60M 30.41M
Interest expense 3.73M 1.09M 0.09M 0.77M 0.02M
Tax provision - 0.03M 0.03M 0.03M 0.05M
Interest income - 0.96M 1.56M 0.80M 0.05M
Net interest income - -0.20M 1.47M 0.77M 0.02M
Income tax expense -1.18M 0.03M -0.94M 0.03M 0.05M
Total revenue 14.61M 12.72M 10.32M 11.25M 10.49M
Total operating expenses 10.22M 35.21M 28.04M 32.70M 30.32M
Cost of revenue 26.50M 1.75M 1.31M 1.55M 1.71M
Total other income expense net -3.98M 1.02M -1.69M 1.70M 1.69M
Net income from continuing ops - -23.24M -19.79M -20.52M -19.87M
Net income applicable to common shares - -23.24M -19.79M -20.52M -19.87M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 34.66M 41.66M 46.99M 68.74M 58.70M
Intangible assets 7.54M 10.19M 13.31M 12.04M 8.74M
Other current assets 1.35M 0.69M 0.86M 0.54M 0.97M
Total liab 24.47M 21.16M 6.24M 7.86M 7.66M
Total stockholder equity 10.19M 20.50M 40.74M 60.88M 51.04M
Other current liab 4.44M 2.60M 1.73M 1.03M 0.93M
Common stock 349.86M - 336.15M 336.09M 307.56M
Capital stock - 336.15M 336.15M 336.09M 307.56M
Retained earnings -379.10M -354.19M -330.95M -311.16M -290.64M
Other liab - - - 0.86M 0.41M
Good will 2.63M 2.78M 2.72M 2.73M 2.63M
Other assets - - - - 0.26M
Cash 15.29M 22.18M 24.63M 45.71M 40.73M
Cash and equivalents - - - 13.55M 31.29M
Total current liabilities 6.18M 5.66M 4.66M 5.85M 7.24M
Current deferred revenue - - 1.49M 3.16M 3.51M
Net debt 1.31M - -23.49M -44.26M -40.56M
Short term debt 0.30M - 0.33M 0.30M 0.17M
Short long term debt total 16.60M - 1.14M 1.45M 0.17M
Other stockholder equity 389.28M - - 8.05M 34.13M
Property plant equipment - - - 1.95M 0.42M
Total current assets 23.53M 27.51M 29.46M 51.94M 46.66M
Long term investments - 0.07M 0.05M 0.08M 0.07M
Net tangible assets - - - 46.11M 39.68M
Net receivables 4.68M 1.93M 3.20M 3.84M 3.41M
Long term debt - 13.79M - - -
Inventory 2.21M 0.86M 0.76M 0.81M 0.93M
Accounts payable 1.44M 1.06M 1.10M 1.35M 2.64M
Accumulated other comprehensive income 39.42M - 35.55M 35.95M 34.13M
Non currrent assets other 0.02M 0.23M 13.31M -16.80M 0.18M
Non current assets total 11.13M 14.15M 17.53M 16.80M 12.04M
Capital lease obligations - 0.70M 1.14M 1.45M 0.17M
Long term debt total - - - 1.15M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.99M -3.10M -6.04M -5.22M
Change to liabilities - - - -0.89M 1.53M
Total cashflows from investing activities -1.27M -0.99M -3.10M -6.04M -5.22M
Net borrowings - 15.97M - -0.42M -0.37M
Total cash from financing activities 15.90M 13.64M -0.48M 27.93M 39.92M
Change to operating activities - - - 0.17M -2.79M
Net income -24.91M -23.24M -19.79M -20.52M -19.87M
Change in cash -6.90M -2.45M -21.08M 4.98M 21.05M
Begin period cash flow 22.18M 24.63M 45.71M 40.73M 19.68M
End period cash flow 15.29M 22.18M 24.63M 45.71M 40.73M
Total cash from operating activities -20.03M -14.64M -17.79M -18.05M -15.66M
Issuance of capital stock - - 0.06M 30.02M 42.50M
Depreciation - - 2.25M 0.68M 1.24M
Other cashflows from investing activities - -0.93M -3.02M - -
Dividends paid - - - -0.42M -0.37M
Change to inventory -1.35M - 0.05M 0.12M -0.55M
Change to account receivables -1.07M - 1.18M 0.18M 0.04M
Sale purchase of stock - 0.00M -0.06M -1.52M -2.21M
Other cashflows from financing activities -0.34M -2.33M -0.48M 0.28M 0.37M
Change to netincome - - - 0.30M 2.95M
Capital expenditures 0.07M 0.99M 3.10M 6.04M 5.22M
Change in working capital -0.92M -18.88M 0.41M 0.29M -0.52M
Stock based compensation - - -0.68M 0.75M 3.00M
Other non cash items 5.80M -14.64M 0.02M 1.79M 2.97M
Free cash flow -20.10M -15.63M -20.89M -24.09M -20.89M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IPD
Impedimed Ltd		 -
-%		 0.00 - - 1.00 1.44 1.09 -9.34
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Impedimed Ltd

ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.

5900 Pasteur Court, Carlsbad, CA, United States, 92008

760 585 2100

https://www.impedimed.com

66

Name Title Year Born
Mr. Timothy Cruickshank Chief Financial Officer NA
Mr. Shashi Tripathi COO, CTO & Chief Customer Officer NA
Mr. Dennis Schlaht Sr. VP of R&D and Technology NA
Ms. Catherine Kingsford Sr. VP of Medical Affairs NA
Mr. David W. Anderson B.S. Exec. Director 1954
Mr. Richard P. Valencia MD & CEO 1962
Mr. Michael John Bassett Chief Commercial Officer, Sr. VP of Corp. & Strategic Devel. and GM of Renal NA
Ms. Nancy T. Deisinger Sr. VP of HR NA
Dr. Thomas Schenk Chief Medical Officer NA
Ms. Leanne Ralph AAICD, ACIS, BBus Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…